Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Staidson (Beijing) Biopharmaceuticals Co. Ltd. is currently managing 1 pending office action. This active matter is being handled by 1 distinct examiner, EDGINGTONGIORDANO, FRANCESCA. The data shows that there are 0 distinct art units associated with this pending activity, which indicates a specific administrative placement for the application. With only 1 pending office action in the portfolio, the company's current prosecution efforts are entirely focused on this single interaction at the USPTO. The absence of a listed technology area suggests a unique or cross-disciplinary application.
EDGINGTONGIORDANO, FRANCESCA is the busiest examiner for the portfolio, currently overseeing 1 pending office action. For practitioners, this means that the immediate success of the portfolio depends on the specific requirements and feedback from this 1 distinct examiner. There are no other examiners or art units involved in the pending workload to provide a comparison or alternative path for patent acquisition. The presence of 0 distinct art units and 1 distinct examiner simplifies the tracking of the portfolio but places significant importance on the outcome of this 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| EDGINGTONGIORDANO, FRANCESCA | 1 | 70.8% | +31.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18574825 | ANTIBODY THAT SPECIFICALLY RECOGNIZES CD40 AND APPLICATION THEREOF | EDGINGTONGIORDANO, FRANCESCA | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18574825 | ANTIBODY THAT SPECIFICALLY RECOGNIZES CD40 AND APPLICATION THEREOF | EDGINGTONGIORDANO, FRANCESCA | — | §112 | Non-Final OA | — | Pending | Dec 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial